These launches belong to what Oelrich called “must-win battles” at Bayer as Xarelto loss of exclusivity reaches “full swing” ...

As the J.P. Morgan Healthcare Conference enters its second day, we're tracking presentations from GSK, Novartis, Sanofi, Eli ...

Germany is widely recognized as one of the leading countries in the pharmaceutical industry boasting a rich history of innovation cutting-edge research and global influence With its well-established i ...

A Washington jury ordered Bayer to pay $100 million to individuals sickened by toxic PCBs at a Seattle school, marking the latest courtroom challenge for the company. Meanwhile, Pfizer is reducing its ...

Bayer today announced topline results of the Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an investigational gadolinium-based contrast agent (GBCA) for use in magnetic ...

Bayer is just the latest in a string of big pharma companies to invest in firms ... Bayer's protein engineering know-how for use in CRISPR products as well as Bayer's extensive expertise and ...

Pharmaceutic, chemical company Monsanto was found liable by a Washington jury for $100 million on Tuesday, according to ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on Regeneron (REGN – Research Report) yesterday and set a price target of ...

However, Bayer's top-selling pharma product Xarelto (rivaroxaban), an anticoagulant, continued to succumb to generic competition with a near-11% fall to €904 million. The solid quarter is ...

Health news updates include the EU contemplating curbs on Chinese medical device makers, Pfizer reducing its stake in Haleon, toothpaste lawsuits over fluoride, Eli Lilly’s stock drop, biopharma ...